TY  - JOUR

T1  - Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase

JO  - The Lancet Diabetes & Endocrinology

UR  - http://eprints.whiterose.ac.uk/163983/

PY  - 2020/09/01

AU  - Pivonello R

AU  - Fleseriu M

AU  - Newell-Price J

AU  - Bertagna X

AU  - Findling J

AU  - Shimatsu A

AU  - Gu F

AU  - Auchus R

AU  - Leelawattana R

AU  - Lee EJ

AU  - Kim JH et al

ED  - 

DO  - DOI: 10.1016/s2213-8587(20)30240-0

PB  - Elsevier

VL  - 8

IS  - 9

SP  - 748

EP  - 761

Y2  - 2024/12/22

ER  -